Avinash G Dinmohamed
Overview
Explore the profile of Avinash G Dinmohamed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zijlstra M, Snijders R, de Boer F, Chamuleau M, Fransen H, Oerlemans S, et al.
Eur J Haematol
. 2025 Jan;
PMID: 39888067
Comprehensive insights are lacking into why patients with hematological malignancies (HMs) receive no cancer-directed treatment. We evaluated socio-demographic and cancer-related characteristics, decision-making rationales, and overall survival in patients with three...
2.
Kaplan Z, van Leeuwen N, van Klaveren D, Visser O, Posthuma E, van Lammeren-Venema D, et al.
BMJ Oncol
. 2025 Jan;
3(1):e000264.
PMID: 39886140
Objective: Acute myeloid leukaemia (AML) prognosis is enhanced with intensive remission induction chemotherapy (ICT) in eligible patients. However, ICT eligibility perceptions may differ among healthcare professionals. This nationwide, population-based study...
3.
Eggermont C, Hollatz A, Wakkee M, Louwman M, Dinmohamed A, Posthuma E, et al.
Br J Dermatol
. 2025 Jan;
PMID: 39854282
Background: Patients with haematologic malignancies are at increased risk of developing skin cancer and often experience worse skin cancer-related outcomes. However, there is a lack of nationwide, population-based data with...
4.
Maas C, Kent D, Dinmohamed A, van Klaveren D
medRxiv
. 2025 Jan;
PMID: 39763519
Background: Risk-based analyses are increasingly popular for understanding heterogeneous treatment effects (HTE) in clinical trials. For time-to-event analyses, the assumption that high-risk patients benefit most on the clinically important absolute...
5.
van der Straten L, Levin M, Dinnessen M, Visser O, Posthuma E, Doorduijn J, et al.
Hemasphere
. 2024 Nov;
8(11):e70015.
PMID: 39534384
Chronic lymphocytic leukemia (CLL) manifests heterogeneously with varying outcomes. This population-based study examined causes of death (CODs), as registered by the physician who established the death, among 20,588 CLL patients...
6.
van Bergen M, Kamphuis P, de Graaf A, Salzbrunn J, Koorenhof-Scheele T, van Zeventer I, et al.
Am J Hematol
. 2024 Oct;
99(12):2402-2405.
PMID: 39429216
No abstract available.
7.
Maas C, van Klaveren D, Durmaz M, Visser O, Issa D, Posthuma E, et al.
Blood Cancer J
. 2024 Sep;
14(1):157.
PMID: 39266543
First-line treatment for advanced-stage diffuse large B-cell lymphoma (DLBCL) typically involves 6x R-CHOP21 or 6x R-CHOP21 with two additional rituximab administrations (6x R-CHOP21 + 2 R). In contemporary practice, this...
8.
Hermans S, van der Maas N, van Norden Y, Dinmohamed A, Berkx E, Huijgens P, et al.
JAMA Oncol
. 2024 Aug;
10(10):1426-1436.
PMID: 39207765
Importance: The use of real-world data (RWD) external control arms in prospective studies is increasing. The advantages, including the immediate availability of a control population, must be balanced with the...
9.
Pennings E, Durmaz M, Visser O, Posthuma E, Issa D, Chamuleau M, et al.
Blood Cancer J
. 2024 Jan;
14(1):3.
PMID: 38177115
No abstract available.
10.
Klein S, Huls G, Visser O, Kluin-Nelemans H, Dinmohamed A
Blood Adv
. 2023 Nov;
7(24):7554-7563.
PMID: 37934881
Myelodysplastic and myeloproliferative neoplasms (MDS/MPN) with neutrophilia, until recently called atypical chronic myeloid leukemia (aCML), being part of the MDS/MPN is a very rare disease with poor prognosis. Although emerging...